Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes

M. Mráz, Š. Pospíšilová, K. Malinová, I. Šlapák, J. Mayer

. 2009 ; 50 (3) : 506-509.

Jazyk angličtina Země Velká Británie

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11020696

Grantová podpora
NR9293 MZ0 CEP - Centrální evidence projektů

E-zdroje

NLK Medline Complete (EBSCOhost) od 1998-01-01

MicroRNAs (miRNAs) are short, non-coding RNAs, which function as evolutionary conserved regulators of a gene expression. They have essential roles in development, cell differentiation, proliferation, apoptosis and chromosome structure. MiRNAs constitute about 3-5% of predicted genes in the human genome (i.e. about 1000); and 20-30% of the protein-coding genes are estimated to be regulated by the miRNAs. The primary evidence that miRNAs possibly act as a novel class of oncogenes/tumor-suppressors comes from the discovery of the miR-15a and miR-16-1 in 13q14 region deleted in chronic lymphocytic leukemia (CLL). Moreover, miRNA signatures have been used to classify tumor types. There have recently been several reports on the miRNAs role in CLL pathogenesis and disease subtypes (according to IgV(H) mutation status). In this report, we will review the published observations and present our miRNA profiling data in aggressive CLL with TP53 abnormalities (deletion and/or mutation of p53 gene). We have identified a deregulated miRNA expression pattern (down regulation of miR-34a, miR-29 and miR-17-5p) in these samples, compared to cells with wild-type TP53. It has previously been shown that miR-34a is directly regulated by p53 and targets BCL-2, miR-29c regulates the MCL-1 and TCL-1 proto-oncogenes and the miR-17-5p targets important cell cycle regulatory molecules. Consequently, these three miRNAs could potentially play important roles in the pathogenesis of aggressive CLL.

000      
02900naa 2200349 a 4500
001      
bmc11020696
003      
CZ-PrNML
005      
20140718134736.0
008      
110629s2009 xxk e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mráz, Marek $7 xx0122131 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
245    10
$a MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes / $c M. Mráz, Š. Pospíšilová, K. Malinová, I. Šlapák, J. Mayer
314    __
$a Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic. marek.mraz@email.cz
520    9_
$a MicroRNAs (miRNAs) are short, non-coding RNAs, which function as evolutionary conserved regulators of a gene expression. They have essential roles in development, cell differentiation, proliferation, apoptosis and chromosome structure. MiRNAs constitute about 3-5% of predicted genes in the human genome (i.e. about 1000); and 20-30% of the protein-coding genes are estimated to be regulated by the miRNAs. The primary evidence that miRNAs possibly act as a novel class of oncogenes/tumor-suppressors comes from the discovery of the miR-15a and miR-16-1 in 13q14 region deleted in chronic lymphocytic leukemia (CLL). Moreover, miRNA signatures have been used to classify tumor types. There have recently been several reports on the miRNAs role in CLL pathogenesis and disease subtypes (according to IgV(H) mutation status). In this report, we will review the published observations and present our miRNA profiling data in aggressive CLL with TP53 abnormalities (deletion and/or mutation of p53 gene). We have identified a deregulated miRNA expression pattern (down regulation of miR-34a, miR-29 and miR-17-5p) in these samples, compared to cells with wild-type TP53. It has previously been shown that miR-34a is directly regulated by p53 and targets BCL-2, miR-29c regulates the MCL-1 and TCL-1 proto-oncogenes and the miR-17-5p targets important cell cycle regulatory molecules. Consequently, these three miRNAs could potentially play important roles in the pathogenesis of aggressive CLL.
590    __
$a bohemika - dle Pubmed
650    _2
$a down regulace $7 D015536
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x etiologie $x genetika $7 D015451
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a mutace $7 D009154
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pospíšilová, Šárka, $d 1969- $7 xx0101843 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
700    1_
$a Plevová, Karla $7 xx0158852 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
700    1_
$a Šlapák, Ivo, $d 1952- $7 jn20000402849 $u Department of Paediatric Otorhinolaryngology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
700    1_
$a Mayer, Jiří, $d 1960- $7 nlk20000083651 $u Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematooncology, University Hospital Brno and Medical Faculty MU, Brno, Czech Republic
773    0_
$t Leukemia & Lymphoma $g Roč. 50, č. 3 (2009), s. 506-509 $w MED00003140
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110721122628 $b ABA008
991    __
$a 20140718135039 $b ABA008
999    __
$a ok $b bmc $g 864223 $s 727087
BAS    __
$a 3
BMC    __
$a 2009 $b 50 $c 3 $d 506-509 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
GRA    __
$a NR9293 $p MZ0
LZP    __
$a 2011-3B09/BBjvme

Najít záznam